Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 17/20 | 0.70 |
| ▸ | AXL | P30530 | 3/20 | 0.70 |
| ▸ | KDR | P35968 | 3/20 | 0.70 |
| ▸ | MST1R | Q04912 | 3/20 | 0.70 |
| ▸ | FLT3 | P36888 | 2/20 | 0.70 |
| ▸ | JAK2 | O60674 | 2/20 | 0.70 |
| ▸ | EGFR | P00533 | 2/20 | 0.70 |
| ▸ | FLT1 | P17948 | 2/20 | 0.70 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.70 |
| ▸ | RPS6KB1 | P23443 | 2/20 | 0.70 |
| ▸ | FLT4 | P35916 | 2/20 | 0.70 |
| ▸ | TEK | Q02763 | 2/20 | 0.70 |
| ▸ | BTK | Q06187 | 2/20 | 0.70 |
| ▸ | PLK4 | O00444 | 1/20 | 0.70 |
| ▸ | STK25 | O00506 | 1/20 | 0.70 |
| ▸ | CIT | O14578 | 1/20 | 0.70 |
| ▸ | AURKA | O14965 | 1/20 | 0.70 |
| ▸ | CHUK | O15111 | 1/20 | 0.70 |
| ▸ | MUSK | O15146 | 1/20 | 0.70 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL409723 | 1.00 | MET (0.70) | METAXLKDRMST1RFLT3 | |
| SCHEMBL29885881 | 1.00 | MET (0.70) | METAXLKDRMST1RFLT3 | |
| Water SCHEMBL2452885 | 0.99 | MET (0.69) | METAXLKDRMST1RFLT3 | |
| SCHEMBL371886 | 0.93 | MET (0.61) | METAXLKDRMST1RFLT3 | |
| SCHEMBL411270 | 0.93 | MET (0.63) | METAXLKDRMST1RFLT3 | |
| SCHEMBL372071 | 0.93 | MET (0.73) | METAXLKDRMST1RFLT3 | |
| SCHEMBL372154 | 0.92 | MET (0.59) | METAXLKDRMST1RFLT3 | |
| SCHEMBL372079 | 0.92 | MET (0.58) | METAXLKDRMST1RFLT3 | |
| SCHEMBL371960 | 0.92 | MET (0.64) | METAXLKDRMST1RFLT3 | |
| SCHEMBL371626 | 0.91 | MET (0.63) | METAXLKDRMST1RFLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 230 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220356494-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2022-11-10 | — | — | US | claimed |
| US-11331313-B2 | KCC2 expression enhancing compounds and uses thereof | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2022-05-17 | — | — | US | claimed |
| US-20210253530-A9 | C-MET MODULATORS AND METHODS OF USE | EXELIXIS, INC. | 2021-08-19 | — | — | US | claimed |
| US-20200331860-A1 | C-Met Modulators and Methods of Use | EXELIXIS INC (US) | 2020-10-22 | — | — | US | claimed |
| EP-2101759-B1 | METHODS OF USING MEK INHIBITORS | EXELIXIS INC (US) | 2018-10-10 | — | — | EP | claimed |
| US-20170355678-A1 | C-Met Modulators and Methods of Use | EXELIXIS INC (US) | 2017-12-14 | — | — | US | claimed |
| US-20160046672-A1 | STAPLING eIF4E INTERACTING PEPTIDES | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2016-02-18 | — | — | US | claimed |
| US-20150376133-A1 | C-Met Modulators and Methods of Use | EXELIXIS, INC. | 2015-12-31 | — | — | US | claimed |
| US-20150246946-A1 | PEPTIDES AND METHODS FOR TREATING CANCER | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2015-09-03 | — | — | US | claimed |
| US-8673912-B2 | Crystalline Forms on N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]-quinolin-4-yl}oxy)phenyl]-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide | EXELIXIS, INC. (US) | 2014-03-18 | — | — | US | claimed |
| US-8314232-B2 | Preparation of a quinolinyloxydiphenylcyclopropanedicarboxamide | GLAXOSMITHKLINE LLC (US) | 2012-11-20 | — | — | US | claimed |
| US-20120270872-A1 | Crystalline Forms of N-[3-fluoro-4-(oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide | EXELIXIS, INC. (US) | 2012-10-25 | — | — | US | claimed |
| US-20120184523-A1 | C-Met Modulators and Method of Use | EXELIXIS, INC. (US) | 2012-07-19 | — | — | US | claimed |
| EP-2454238-A1 | CRYSTALLINE FORMS OF N-[3-FLUORO-4-({6-(METHYLOXY)-7-[(3-MORPHOLIN-4-YLPROPYL)OXY]-QUINOLIN-4-YL}OXY)PHENYL]-N'-(4-FLUOROPHENYL)CYCLOPROPANE-1, 1-DICARBOXAMIDE | Exelixis, Inc. (US) | 2012-05-23 | — | — | EP | claimed |
| US-20110077233-A1 | C-Met Modulators and Method of Use | EXELIXIS, INC. (US) | 2011-03-31 | — | — | US | claimed |
| WO-2011009095-A1 | CRYSTALLINE FORMS OF N-[3-FLUORO-4-({6-(METHYLOXY)-7-[(3-MORPHOLIN-4-YLPROPYL)OXY]-QUIN0LIN-4-YL}OXY)PHENYL]-N'-(4-FLUOROPHENYL)CYCLOPROPANE-1, 1-DICARBOXAMIDE | EXELIXIS, INC. (US) | 2011-01-20 | — | — | WO | claimed |
| US-20100081805-A1 | Preparation of a Quinolinyloxydiphenylcyclopropanedicarboxamide | EXELIXIS, INC. | 2010-04-01 | — | — | US | claimed |
| US-20080166359-A1 | Methods of using MEK inhibitors | EXELIXIS, INC. | 2008-07-10 | — | — | US | claimed |
| US-20070225307-A1 | C-MET MODULATORS AND METHOD OF USE | EXELIXIS, INC. (US) | 2007-09-27 | — | — | US | claimed |
| US-20070054928-A1 | c-Met modulators and methods of use | EXELIXIS, INC. (US) | 2007-03-08 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200331860-A1 | C-Met Modulators and Methods of Use | FLT4, FLT1, MET | MET 3/4885AXL 109/4885KDR 4/4885 |
| US-20070054928-A1 | c-Met modulators and methods of use | FLT4, FLT1, MET | MET 3/4885AXL 109/4885KDR 4/4885 |
| US-11331313-B2 | KCC2 expression enhancing compounds and uses thereof | MECP2, SLC1A2, GRIN2C | MET 3718/4885AXL 4696/4885KDR 2827/4885 |
| US-20220356494-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER | SRC, BCOR, CTTN | MET 244/4885AXL 1592/4885KDR 721/4885 |
| US-20150376133-A1 | C-Met Modulators and Methods of Use | FLT4, FLT1, MET | MET 3/4885AXL 109/4885KDR 4/4885 |
| US-20170355678-A1 | C-Met Modulators and Methods of Use | FLT4, FLT1, MET | MET 3/4885AXL 109/4885KDR 4/4885 |
| US-20210253530-A9 | C-MET MODULATORS AND METHODS OF USE | FLT4, FLT1, MET | MET 3/4885AXL 109/4885KDR 4/4885 |
| US-20160046672-A1 | STAPLING eIF4E INTERACTING PEPTIDES | EIF4EBP1, EIF4E, EIF4G2 | MET 2104/4885AXL 3580/4885KDR 3638/4885 |
| US-20080166359-A1 | Methods of using MEK inhibitors | BRAF, NRAS, KRAS | MET 312/4885AXL 769/4885KDR 1023/4885 |
| US-20070225307-A1 | C-MET MODULATORS AND METHOD OF USE | FLT4, MET, FLT1 | MET 2/4885AXL 241/4885KDR 5/4885 |
| US-20150246946-A1 | PEPTIDES AND METHODS FOR TREATING CANCER | TP53, MDM4, MDM2 | MET 480/4885AXL 1468/4885KDR 1025/4885 |
| US-20120184523-A1 | C-Met Modulators and Method of Use | FLT4, MET, FLT1 | MET 2/4885AXL 241/4885KDR 5/4885 |
| US-20110077233-A1 | C-Met Modulators and Method of Use | FLT4, MET, FLT1 | MET 2/4885AXL 241/4885KDR 5/4885 |
| US-20100081805-A1 | Preparation of a Quinolinyloxydiphenylcyclopropanedicarboxamide | QDPR, CBR3, NQO2 | MET 3908/4885AXL 3026/4885KDR 1336/4885 |
| US-20120270872-A1 | Crystalline Forms of N-[3-fluoro-4-(oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide | NOLC1, FN3KRP, PRKCA | MET 1212/4885AXL 509/4885KDR 1727/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.